Epigenetics and Cancer Therapy
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".
Deadline for manuscript submissions: 22 June 2024 | Viewed by 974
Special Issue Editors
Interests: cancer; lung cancer; MDR; genetics; genetic markers; drug transporters; chemotherapy; genotoxicology
Special Issue Information
Dear Colleagues,
Cancer is a heterogeneous disease and one of the leading causes of death worldwide, which is affected by genetic and epigenetic modulations in the regulation of cell division. One of the most serious obstacles in applied cancer therapy is the occurrence of multidrug resistance, which may evolve due to oncogene mutations, modifications in the tumor microenvironment, tumor diversification, target site mutations or epigenetic adjustment. The phenomenon of multidrug resistance may occur naturally but acquiring it during chemotherapy is more recurrent. Consequently, recent laboratory studies and clinical trials have analyzed remarkable drugs for targeted and personalized therapy; however, the given drug treatment becomes inefficient due to the development of multidrug resistance. Despite the emergence of new therapies, patients—mostly in advanced stages of the disease—are still being treated following a set protocol including surgery, radiation and chemotherapy or a combination of the above.
In this context, we present a Special Issue, with Dr. Luca Jaromi and Dr. Gellert Gerencser as Guest Editors, which will collate papers aimed at identifying genetic markers that influence the outcome of various cancer treatments, including chemotherapy agents, chemoradiotherapy and radiation techniques. We invite papers that underscore the sophisticated treatment approaches as well as the relationships between accumulation of various cancer therapeutic agents and expression levels of target genes, thereby contributing to a better understanding and more effective treatment of cancer or malignant tumours.
Dr. Luca Járomi
Dr. Gellért Gerencsér
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- epigenetics
- cancer therapy
- multidrug resistance (MDR)
- accumulation
- biomarkers
